Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

DOI: 10.1634/theoncologist.2018-0740

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text